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Abstract 
Underlying mechanisms of individual variation in severity of influenza infection and response to 
vaccination are poorly understood. We investigated the effect of reduced heme oxygenase-1 
(HO-1) expression on vaccine response and outcome of influenza infection. HO-1-deficient and 
wild-type (WT) mice (kingdom, Animalia; phylum, Chordata; genus/species, Mus musculus) 
were infected with influenza virus A/PR/8/34 with or without prior vaccination with an 
adenoviral-based influenza vaccine. A genome-wide association study evaluated the expression 
of single-nucleotide polymorphisms (SNPs) in the HO-1 gene and the response to influenza 
vaccination in healthy humans. HO-1-deficient mice had decreased survival after influenza 
infection compared to WT mice (median survival 5.5 vs. 6.5 d, P=0.016). HO-1-deficient mice 
had impaired production of antibody following influenza vaccination compared to WT mice 
(mean antibody titer 869 vs. 1698, P=0.02). One SNP in HO-1 and one SNP in the constitutively 
expressed isoform HO-2 were independently associated with decreased antibody production after 
influenza vaccination in healthy human volunteers (P=0.017 and 0.014, respectively). HO-1 
deficient mice were paired with sex- and age-matched WT controls. HO-1 affects the immune 
response to both influenza infection and vaccination, suggesting that therapeutic induction of 
HO-1 expression may represent a novel adjuvant to enhance influenza vaccine effectiveness.—
Cummins, N. W., Weaver, E. A., May, S. M., Croatt, A. J., Foreman, O., Kennedy, R. B., 
Poland, G. A., Barry, M. A., Nath, K. A., Badley, A. D. Heme oxygenase-1 regulates the 
immune response to influenza virus infection and vaccination in aged mice. 
Keywords: single-nucleotide polymorphism, pathogenesis, cytokine 
Seasonal influenza virus infection is a major cause of morbidity and mortality worldwide, 
causing an estimated 36,000 deaths each year in the United States alone, according to the Centers 
for Disease Control and Prevention. While vaccination is the primary method of preventing 
morbidity and mortality from influenza virus infection, the response rate is highly variable and is 
markedly decreased in the older adult population. Similarly, clinical influenza infection ranges 
from a mild self-limited illness to severe respiratory failure and adult respiratory distress 
syndrome accompanied by multiorgan system failure and death. The immune response to 
influenza infection is complex and involves virus recognition by Toll-like receptors (TLRs), 
activation of innate immune effector mechanisms, production of proinflammatory and anti-
inflammatory chemokines and cytokines, and coordinated antigen presentation, leading to 
adaptive Th1 and Th2 responses (1). The production of protective, influenza-neutralizing 
antibodies in response to infection or vaccination is regulated by antigen-specific CD4+ T-cell 
interactions with antigen-presenting cells expressing human leukocyte antigen (HLA) class II 
molecules in association with viral antigens (1). Known risk factors for both decreased vaccine 
response and more severe illness include age, chronic illness, pregnancy, and 
immunosuppression (2). Genetic factors also contribute to both decreased vaccine response and 
more severe influenza illness, including specific HLA haplotypes, and polymorphisms in critical 
mediators of the immune response, such as TLRs (TLR3), proinflammatory cytokines (IL-6, IL-
12, IL-18, and IFNγ), and cytokine receptors (IL-1R, IL-2R, IL-4R, IL-10R, IL-12R, and TNFR) 
(1, 3). 
Heme oxygenase (HO) is the rate-limiting enzyme involved in the degradation of heme, which 
yields carbon monoxide (CO), iron, and biliverdin; biliverdin is subsequently converted to 
bilirubin via the catalytic effects of biliverdin reductase. HO exists in two isoforms. HO-1 is 
inducibly expressed in response to numerous cellular stressors in virtually all tissues, and HO-2 
is constitutively expressed in cells (4, 5). In addition to its cytoprotectant, antioxidant, and 
antiapoptotic properties, HO-1 is generally anti-inflammatory in nature through effects that 
reflect its degradation of heme and the products that are generated (6, 7); specifically, heme is 
recognized as a proinflammatory species, while CO and bile pigments can interrupt multiple 
steps in inflammatory processes, including the production of proinflammatory Th1 cytokines; 
activation of leukocytes and the endothelium; the activation of proinflammatory transcription 
factors; TLR signaling; NADPH oxidase activity and signaling; and the behavior of dendritic 
cells (5, 6). 
HO-1 expression in the immune response to multiple infections, including gram-positive and 
gram-negative sepsis, tuberculosis, and cerebral malaria, generally dampens pathological 
consequences of injury, thereby improving host survival, but sometimes with the result of 
decreasing pathogen clearance (8–10). Intranasal infection of two strains of wild-type (WT) mice 
with influenza virus has been demonstrated to result in increased HO-1 expression and activity 
over background in the lungs compared to uninfected mice (11). Other experiments with mice 
engineered to overexpress HO-1 in the lungs, which are subsequently infected with influenza 
virus, have demonstrated decreased lung inflammation and mortality compared to mice with 
normal expression of HO-1, suggesting that HO-1 expression prevents the development of an 
overactive immune response and collateral tissue damage (12). 
Clinical observations suggest that experimental evidence indicating the cytoprotective and anti-
inflammatory effects of HO also applies to human disease. Homozygous deletion in the HO-1 
gene, for example, leads to death in childhood, while polymorphisms in the human HO-1 
promoter region, characterized by long GT repeats accompanied by decreased HO-1 expression 
and/or HO activity, have been associated with poor outcomes in many inflammatory conditions, 
including transplant allograft rejection, ischemia/reperfusion injury, cardiovascular disease, and 
hemorrhagic stroke, among others (5, 13). There are very few studies of human HO-1 single-
nucleotide polymorphisms (SNPs) and the propensity to human disease, but one such study 
suggests that the frequency of multiorgan dysfunction in critically ill patients may be associated 
with certain HO-1 SNPs (14). 
The purpose of the current study is to investigate the effect of reduced HO-1 expression on 
vaccine response and the outcome of influenza virus infection in a murine model, and the effect 
of SNPs in HO genes on the generation of protective neutralizing antibodies in human subjects 
receiving influenza vaccination, in order to discern the clinical relevance of HO-1 on influenza 
infection and influenza vaccination response. 
MATERIALS AND METHODS 
Murine model 
All animal studies were performed in accordance with federal guidelines and were approved by 
the Institutional Animal Care and Use Committee at Mayo Clinic (Rochester, MN, USA). HO-
1−/− mice, on a predominantly C57BL/6 background, were generated as described previously (24, 
25), by breeding HO-1+/− females with HO-1−/− males. Wild-type (WT) controls were generated 
and selected from the same colony from heterozygote pairings. Genotypes of offspring mice 
were confirmed by PCR of tail DNA using the following primers: HO-1 WT, forward 5′-
AGAGTACACTGACTGTGGGTG-3′ and reverse 5′-AGGGCCGTGTAGATATGGTAC-3′; 
HO-1 mutant, forward 5′-GAAGGTGAGATGACAGGAGATC-3′ and reverse 5′-
GCTTGGGTGGAGAGGCTATTC-3′. Mice between the ages of 50 and 80 wk of age were 
utilized throughout the study to model effects seen in older humans, who are at increased risk of 
severe influenza disease and poor vaccine response. Younger mice between the ages of 16 and 
20 wk were utilized where indicated. HO-1−/− mice were paired with sex- and age-matched WT 
controls for each experiment. 
Murine vaccination model 
First-generation replication defective (E1/E3 deleted) Ad5 vectors that expressed the codon-
optimized hemagglutinin (HA) gene of A/PR/8/34 were constructed using the Ad-Easy system 
(Agilent Technologies, Santa Clara, CA, USA) in 293A cells, as described previously (26). All 
adenoviruses were purified by CsCl banding and quantitated by optical density (OD260). Mice 
were restrained using the scruff method and immunized with a total of 1010 vp of adenovirus 
expressing the A/PR/8/34 HA gene divided in 25 μl of saline injected into each quadriceps 
muscle. At 3 wk postimmunization, blood was drawn by retroorbital puncture, and serum was 
collected using Becton Dickinson microtainer tubes with serum separator (Becton Dickinson, 
Franklin Lakes, NJ, USA). Starting at a dilution of 1:5, sera were diluted 2-fold in 50 μl of DPBS 
in a 96-well, nonsterile, non-tissue culture-treated, round-bottom microtiter plate. Influenza virus 
[4 hemagglutination units (HAU)] in 50 μl was added to the diluted sera and incubated at room 
temperature for 1 h. After incubation, 50 μl of a 1% chicken red blood cell solution was added 
and incubated at room temperature for 1 h. The hemagglutination inhibition (HI) titer was 
determined to be the highest serum dilution to inhibit hemagglutination. 
Influenza virus infection 
Mice were immunized with the Ad-vectored vaccines. At 3 wk after immunization, the mice 
were anesthetized with ketamine (140 mg/kg)/xylazine (5.55 mg/kg) administered 
intraperitoneally. The mice were weighed for baseline measurements. The mice were challenged 
intranasally with 50 times the 50% lethal dose (LD50; Fig. 1A, B) or 100 LD50 (Fig. 1C, D) of 
influenza A/PR/8/34 virus. The mice were placed on their backs, and 10 μl of A/PR/8/34 virus 
was pipetted into each nares for a total volume of 20 μl. The mice were then weighed and 
monitored daily for signs of disease. Mice were humanely euthanized if their body weight 
dropped to 75% of baseline weights. Where noted, after sacrifice, lungs were dissected, perfused, 
fixed in 2% formalin, and embedded in paraffin, and hematoxylin and eosin slides were 
prepared. Microsomal preparations on unfixed lung tissue and subsequent Western blot analysis 
for HO-1 protein expression using an anti-HO-1 antibody (SPA895; StressGen Biotechnologies, 
Victoria, BC, Canada) were performed as described previously (7, 16). 
Lung viral titers 
Mice were infected intranasally with 100 LD50 influenza A/PR/8/34. At 3 d postinfection, the 
mice were euthanized by ketamine/xylazine overdose. The lungs were aseptically removed and 
put into 1.0 ml of sterile PBS. The lungs were homogenized using a VWR PowerMax 
homogenizer (VWR International, Radnor, PA, USA) at full speed for 30 s. The lung 
homogenate was centrifuged at 200 g for 5 min to pellet debris, and the supernatant was 
harvested for analysis. The 50% tissue culture infectious dose (TCID50) was determined using 
Madin-Darby canine kidney (MDCK) cells, as described previously (27). Briefly, the lung 
homogenates were diluted in DMEM containing 5% FBS, 100 U/ml of penicillin, and 100 μg/ml 
of streptomycin in a U-bottom tissue culture-treated 96-well plate. MDCK cells (2.5×104) were 
added to the diluted virus and incubated at 35°C overnight. The following day, the medium was 
removed, and DMEM containing 0.0002% trypsin and antibiotics was added. The cells were 
incubated for 4 d at 35°C. Finally, 50 μl of 0.5% chicken red blood cells were added to each 
well, and the plate was incubated at room temperature for 1 h. The TCID50 was calculated using 
the Reed and Muench technique. 
Multiplex cytokine assay 
Serum samples collected 5 d after vaccination or infectious challenge with 100 LD50 influenza 
virus were assayed for cytokine levels, including IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, 
IL-10, IL-12(p40), IL-12(p70), IL-13, IL-17, eotaxin, granulocyte colony-stimulating factor (G-
CSF), granulocyte-monocyte colony-stimulating factor (GM-CSF), interferon-γ, keratinocyte-
derived chemokine (KC), monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory 
protein-1α (MIP-1α), MIP-1β, regulated on activation normal T cell expressed and secreted 
(RANTES/CCL5), and tumor necrosis factor α (TNF-α). Serum cytokine concentrations were 
measured using a multiplex bead suspension array (Bio-Plex Pro Mouse Cytokine 23-plex 
Assay; cat. no. M60009RDPD; Bio-Rad, Hercules, CA, USA) per manufacturer's protocol. 
Genome-wide association study 
All human studies were performed according to protocols approved by the Institutional Review 
Board of the Mayo Clinic, and informed consent was obtained from each subject. All individuals 
were typed using the Illumina Infinium HumanHap550 BeadChip arrays (Illumina, San Diego, 
CA, USA). Initial QC steps included genotype reproducibility, inheritance by descent, gender 
check, SNP call rate, minor allele frequency, Hardy-Weinberg equilibrium (HWE), and subject 
call rate. We found three pairs of duplicated subjects and removed one data set from each pair. 
Overall, genotype concordance was 97.9%, indicating good reproducibility. The mean call rate 
for SNP typing was 98.2% (range: 36.3% to 100%), and the 6.2% of SNPs with call rates <95% 
were excluded from the analysis, as were monomorphic SNPs and those failing HWE. The mean 
call rate for individuals was 98.6% (range: 50.5–99.99%), and the 71 subjects with call rates 
<95% were excluded from the study. Following the QC steps, our cohort included 147 subjects 
and used data from 526,687 SNPs for the analysis. P values for SNP association analyses were 
adjusted for age at enrollment, ethnicity, and time since immunization. Smallpox-neutralizing 
antibody titers were assessed using a high-throughput, reporter-based viral neutralization assay, 
as described previously (28). Antibody titer is reported as ID50: serum dilution required to inhibit 
50% of viral activity. 
Statistical analysis 
Data are expressed as means ± se or medians [interquartile range (IQR)] for parametric and 
nonparametric measures, respectively, and were compared between 2 groups using the Student's 
t test or Mann-Whitney U test when appropriate, or between multiple groups using 1-way 
analysis of variance. Survival data were compared using Kaplan-Meier curves and the log-rank 
comparison test. Values of P < 0.05 were considered statistically significant. Statistical analysis 
was performed on GraphPad Instat software (GraphPad, La Jolla, CA, USA). 
RESULTS 
Aged HO-1-deficient mice have a worsened outcome compared to WT mice after 
influenza virus challenge 
Because influenza virus infection in mice induces HO-1 expression in the lungs (11), and genetic 
overexpression of HO-1 in the lungs of mice attenuates the course of experimental influenza 
viral infection (12), we questioned whether the absence of HO-1 expression would be associated 
with a more severe illness after influenza virus infection. We chose aged mice because the 
burden of influenza disease is greatest in the older population. First, we confirmed the presence 
of HO-1 protein expression in the lungs of WT mice, and absence of HO-1 protein expression in 
HO-1−/− mice, after influenza virus infection (Supplemental Fig. S1). In unvaccinated animals, 
HO-1−/− mice had a more severe course of influenza illness, with greater weight loss and reduced 
survival (Fig. 1), compared to WT mice using two different infectious challenge doses. For mice 
infected with 50 LD50 influenza virus, HO-1
−/− mice compared to WT experienced a 
nonsignificantly accelerated mortality (Fig. 1A) and a significant increase in weight loss (P=0.03 
at d 5 and 6 after infection, Fig. 1B). For mice infected with 100 LD50 influenza virus, HO-1
−/− 
mice tended to lose more weight after infection compared to WT mice, although the difference 
was not statistically significant (P=0.06 for d 4–6 after infection, Fig. 1D). At the higher dose, 
median survival in the HO-1−/− mice was 24 h shorter compared to the WT mice, (5.5 vs. 6.5 d, 
respectively, P=0.016; Fig. 1C). Therefore, the outcome of influenza virus infection is worse in 
an HO-1-deficient state in aged mice. A mortality difference was not noted in younger HO-1−/− 
compared to WT mice (aged 16-20 wk; Supplemental Fig. S2), suggesting an acquired 
impairment in immunity associated with age. 
Induction of HO-1 exerts anti-inflammatory effects (6, 7). Therefore, we questioned whether the 
reduced survival of HO-1−/− mice following influenza virus infection is associated with altered 
viral replication or altered production of inflammatory cytokines. Viral burden in the lungs 
measured 3 d after infection was not significantly different between WT and HO-1−/− mice 
[median (interquartile range) TCID50/ml of 853 (151, 13653) and 427 (213, 2414), respectively, 
P=0.69]. Similarly, pulmonary lesions in infected WT and HO-1−/− mice were similar and had 
comparable distribution in the small airways (Fig. 2A, B). All infected mice had necrotizing 
bronchiolitis with varying degrees of epithelial necrosis and sloughing. Dense sheets of 
neutrophils often filled the airways, and the adjacent epithelium was variably hyperplastic. 
Pulmonary interstitium was expanded by mixed inflammatory infiltrates comprised of 
lymphocytes, plasma cells, and fewer numbers of macrophages and neutrophils (Fig. 2C, D). 
Alveolar spaces contained proteinaceous fluid admixed with foamy macrophages. The single 
prominent difference that was evident between the HO-1−/− and WT mice was that HO-1−/− mice 
had dense lymphoplasmacytic perivascular infiltrates surrounding many of the pulmonary 
vessels, while in WT mice, these infiltrates were absent or minimal (Fig. 2E, F). These pathology 
findings suggested enhanced inflammation in the HO-1−/− mice. 
Therefore, serum samples from WT and HO-1−/− mice both prior to and 1, 5, and 7 d after 
influenza virus infection were analyzed for the expression of 23 cytokines (Supplemental Table 
S1). At baseline, the serum level of IL-2 was significantly lower in the HO-1−/− mice compared 
to WT (10.9±12.9 vs. 43.2±13.4 pg/ml, P<0.05), although changes in IL-2 after infection were 
not significantly different between the knockout and WT mice. However, mirroring the 
differences seen in lymphoplasmacytic infiltrates in the lung, the HO-1−/− mice had a higher fold 
change in early RANTES expression compared to WT within the first 24 h after infection 
(2.4±2.2-fold increase vs. 0.60±0.24 decrease, P=0.04). This difference in RANTES expression 
did not persist beyond 24 h, (Fig. 3A). Over the course of infection, HO-1−/− mice had an 
increase in MCP-1 expression compared to a decrease in WT mice (P=0.04 for differences in 
slope of linear regression, Fig. 3B). 
Aged HO-1-deficient mice have impaired antibody production in response to 
vaccination 
Because inflammation contributes to T-cell recruitment and the development of T-cell help, 
which favors an optimized B-cell response to vaccination, we questioned whether the HO-1-
deficient state would result in an altered humoral response to vaccination. WT and HO-1−/− mice 
(50–80 wk old) were injected intramuscularly with an adenoviral vector expressing the influenza 
H1 protein or saline vehicle control. HI titers, a measure of protective antibodies against 
influenza virus, were measured in serum collected 21 d after vaccination. The adenoviral-
vaccinated HO-1−/− mice exhibited a 2-fold decrease (P=0.02) in HI titer after immunization 
compared to age- and sex-matched, vaccinated WT mice (Fig. 4A). The WT and HO-1−/− mice 
vaccinated with vehicle control did not generate detectable anti-influenza antibodies (data not 
shown). Because of the high titers of antibody generated in both groups of mice with this vaccine 
approach, there was no significant difference between immunized WT and immunized HO-1−/− 
mice in survival (100 vs. 96%, respectively, data not shown) or weight loss (Fig. 4B) after an 
infectious challenge. However, the decreased antibody production in response to vaccination in 
HO-1−/− mice was associated with elevated levels of IL-5, IL-6, IL-10, IL-12(p40 subunit), MIP-
1α, and MIP-1β in adenoviral-immunized HO-1−/− mice compared to immunized WT mice 
(Table 1). 
Influenza vaccine response in humans is related to polymorphisms in the HO-1 
promoter region 
In humans, the variable expression of HO-1 in response to inflammatory stimuli is associated 
with polymorphisms in the HO-1 gene (5). Because of our data linking antibody response to 
influenza vaccination to HO-1 expression in mice, we questioned whether antibody response to 
influenza vaccination in humans would be associated with SNPs in the HO-1 gene. In a genome-
wide association study of 147 influenza vaccine recipients, one SNP (rs743811) in the HO-1 3′ 
untranslated region, and one intronic SNP (rs2160567) in HO-2, were independently and 
significantly associated with decreased H1-specific HI titers after influenza vaccination (Table 
2). Subjects with 0, 1, and 2 minor alleles in either SNP had median (IQR) H1-specific HI titers 
of 160 (80, 320), 80 (60, 160), and 20 (20, 20) respectively, (P=0.017 and P=0.014, respectively, 
for the HO-1 and HO-2 SNPs). As total HO activity is determined by a combination of basal 
expression of HO-2 and induced expression of HO-1, this supports our murine data, suggesting 
that HO expression is a critical determinant of the response to influenza vaccine. In a 
complementary analysis of healthy recipients of the smallpox vaccine, 2 SNPs in HO-1 
(rs743811, rs5755720) and 2 SNPs in HO-2 (rs2160567, rs11866840) were significantly and 
independently associated with decreases in neutralizing antibody response, (Supplemental Table 
S2). 
DISCUSSION 
It is well recognized that both the severity of influenza infection and the immune response to 
influenza vaccination are highly variable, yet the mechanisms for such interindividual variability 
remain elusive. In the current report, we demonstrate for the first time that HO-1 deficiency 
worsens influenza disease, and reduces vaccine response in an aged murine model, and that 
SNPs in HO-1 and HO-2 affect human influenza vaccine responses. 
HO-1 has been previously investigated in the pathogenesis of influenza. In 2 strains of mice 
(C57BL/6 and C3H/HeJ) infected with influenza A/PR/8/34 (the same viral strain as was used in 
the present murine study), an increase in HO-1 message and activity in the lungs of infected mice 
was associated with improved survival despite similar viral content in the lungs (11). The 
reciprocal experiment of genetic overexpression of HO-1 in the lungs of WT mice by an 
adenoviral vector resulted in improved survival, decreased inflammatory cell infiltration of the 
lung, and decreased apoptosis of respiratory epithelial cells compared to mice with normal HO-1 
expression (12). Our study extends these observations to the HO-1-deficient state, which is 
clinically relevant, given the existence of functional SNPs in the HO-1 gene that lead to variable 
HO-1 expression in humans. 
The exact mechanisms of HO-1-mediated protection in influenza infection were previously 
unclear. The studies mentioned above suggest that HO-1 expression does not have a direct 
antiviral effect. Heme, the cellular substrate of HO-1 metabolism, is an essential prosthetic group 
in many cellular enzymes, but also has multiple cytoxic effects, including oxidative stress, 
induction of DNA damage, cell cycle arrest, mitochondrial toxicity, and apoptosis, when 
insufficiently metabolized (15). Toxic intracellular levels of heme also induce expression of 
MCP-1 through NF-κB signaling (16). In response to influenza infection, respiratory epithelial 
cells and resident monocytes/macrophages produce chemokines, including RANTES and MCP-
1, which preferentially recruit blood mononuclear cells to the site of infection (17, 18). Results of 
our study suggest that HO-1 may have an important role in the control of this local inflammation 
and possibly cell migration and recruitment, since lymphoplasmacytic perivascular infiltrates and 
serum levels of the chemokines RANTES and MCP-1, and not the proinflammatory cytokines 
IL-1, IL-6 or TNF-α, were higher after influenza infection in HO-1−/− mice compared to WT 
mice. Increased MCP-1 expression along with heightened activation of its transcription factor, 
NF-κB, occur in HO-1−/− mice compared to WT in response to other inflammatory stimuli, 
namely intravenous administration of hemoglobin and ischemia/reperfusion injury of the kidney. 
Conversely, HO-1 overexpressing renal epithelial cells exhibit less MCP-1 mRNA and less NF-
κB activation when exposed to proinflammatory stimuli, such as LPS and albumin. In aggregate, 
these prior observations support the association seen in our current study (19, 20). 
It is notable that the worsened influenza disease severity demonstrated in the HO-1−/− mice 
compared to WT mice was not demonstrated in younger mice (aged 16–20 wk) in the current 
study (Supplemental Fig. S2). This finding raises several possibilities worthy of further study, 
including age-related changes in the expression, regulation, or function of HO-1 regulated 
processes and immune mediators, or changes in compensatory mechanisms of heme degradation 
in the setting of insufficient HO-1 induction. 
The role of HO-1 in vaccine response, either in humans or in mice, has not been previously 
reported. Cytokine and chemokine expression plays an important role in the coordinated immune 
response to the vaccine in order to produce adequate immunological protection (1). 
Proinflammatory cytokines and chemokines predominate as a primary response early after 
vaccination, and are followed by secondary anti-inflammatory cytokines after the development 
of adaptive immune responses in a negative feedback loop. Indeed, in the setting of HO-1 
deficiency, our data demonstrate that the serum cytokine profile after vaccination in the HO-1−/− 
mice encompasses an exaggerated production of both proinflammatory and anti-inflammatory 
cytokines (see Table 1). Consistent with these observations are our prior studies, which 
demonstrate that the heightened sensitivity of HO-1−/− mice to lipopolysaccharide is 
accompanied by an exaggerated production of both proinflammatory and anti-inflammatory 
cytokines (7). We speculate that the heightened proinflammatory component of the inflammatory 
response in HO-1−/− mice may underlie the decreased vaccine response: SNPs in genes for both 
IL-6 and IL-12, both of which were abnormally expressed in the vaccinated HO-1−/− mice, have 
been previously reported to be associated with suboptimal response to influenza vaccination in 
humans (1). The finding of a similar association of SNPs with vaccine response in human 
recipients of the trivalent influenza vaccine increases the applicability of our results. The 
association between HI titer and HO-2 polymorphisms in humans is also novel and is consistent 
with our HO-1 data, as HO-2 is the constitutively expressed isoform of heme oxygenase. In fact, 
the association of single nucleotide polymorphisms in HO-1 and HO-2, with vaccine response is 
a particular strength of our study, in that relatively few studies on HO-1 polymorphisms have 
been conducted on SNPs (14, 21, 22), while most have focused on the (GT)n repeat-length 
promoter polymorphism (5, 13). 
In summary, we demonstrate that HO-1 is a regulator of the immune response to both influenza 
infection and vaccination. These findings assume additional importance as the first 
demonstration of pharmacologic induction of HO-1 activity in humans has recently been 
reported (23). In this study, 10 healthy adult volunteers were randomized to receive either hemin 
intravenously at a dose of 3 mg/kg once or vehicle placebo control and followed for 48 h. HO-1 
venous plasma levels and venous leukocyte activity were significantly elevated in 4 of the 5 
recipients of hemin up to 48 h after infusion, with no adverse effects noted on routine 
hematologic and coagulation parameters. HO-1 may, therefore, become a viable, novel target for 
immunomodulatory therapy to improve clinical outcomes in influenza infection and/or to 
improve vaccine effectiveness in subgroups of at-risk individuals, both of which have an obvious 
potential public health effect given the annual morbidity and mortality associated with seasonal 
or pandemic influenza. 
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Figures and Tables 
Figure 1. 
 
Course of influenza infection in WT and HO-1−/− mice. Age- and sex-matched WT and HO-1−/− 
aged mice were challenged with 2 doses (see Materials and Methods) of intranasal influenza 
virus and monitored for weight change and survival for 8 to 10 d. A) Survival was not 
statistically significantly decreased in HO-1−/− mice compared to WT mice after low-dose 
infection (P>0.05, log-rank test). B) HO-1−/− mice lost more weight after low-dose infection 
compared to WT mice. *P = 0.03 at d 5 and 6, Mann-Whitney U test. C) Survival was decreased 
in HO-1−/− mice compared to WT mice after high-dose infection (P=0.016, log-rank test). D) 
HO-1−/− mice tended to lose more weight after high-dose infection compared to WT controls 




Lung histopathology was examined in aged mice at 5 d after intranasal influenza virus infection. 
A–D) Representative images of airway inflammation from uninfected (A, C) and infected (B, D) 




Systemic cytokine expression after influenza infection. A) Fold change in serum RANTES level 
was increased in HO-1−/− mice compared to WT mice at 24 h after influenza infection (P=0.04, 
Mann-Whitney U test), although this did not persist beyond 24 h. B) HO-1−/− mice experienced a 
continued rise in serum MCP-1 levels up to 7 d after infection compared to WT mice, which 





Influenza vaccine response in WT and HO-1 −/− mice. A) HI titers measured in HO-1−/− (n=23) 
and age- and sex-matched WT controls (n=24) at 21 d after vaccination with an adenoviral 
vector expressing H1. B) Immunized mice were subsequently challenged with influenza 
infection, and immunized HO-1−/− mice tended to lose more weight after infectious challenge 




Serum levels of 23 cytokines in WT or HO-1−/− mice 5 d after vaccination with either Ad5.H1 or 






Vehicle Vaccine Vehicle Vaccine 
IL1a 50.4 ± 37.8 69.6 ± 31.2 22.6 ± 6.4 30.8 ± 8.8 0.07 
IL1b 382.0 ± 57.0 387.4 ± 69.7 465.4 ± 218.7 2454.3 ± 2585.5 0.07 
IL2 43.2 ± 13.4 38.0 ± 43.0 10.9 ± 12.9 15.8 ± 14.2 0.22 
IL3 6.8 ± 4.4 8.3 ± 2.4 6.0 ± 5.8 133.7 ± 236.7 0.19 
IL4 7.5 ± 3.2 6.8 ± 0.8 4.7 ± 2.4 6.9 ± 2.8 0.45 
IL5 38.3 ± 5.0 39.5 ± 12.7 33.2 ± 8.1 227.5 ± 160.1 0.03* 
IL6 8.6 ± 1.4 13.4 ± 4.2 12.4 ± 13.3 235.9 ± 411.0 0.047* 
IL9 499.5 ± 84.0 540.0 ± 50.3 467.7 ± 165.7 595.3 ± 36.4 0.33 
IL10 19.2 ± 30.5 30.7 ± 61.4 39.5 ± 39.4 135.3 ± 80.6 0.047* 
IL12 ± p40 478.7 ± 149.5 396.8 ± 115.8 1464.9 ± 951.8 4162.1 ± 3948.8 0.01* 
IL12 ± p70 327.8 ± 103.2 166.1 ± 38.2 200.4 ± 100.0 371.1 ± 40.6 0.01* 
IL13 773.7 ± 228.0 887.5 ± 102.7 634.1 ± 357.9 847.8 ± 147.0 0.45 
IL17 91.9 ± 50.6 91.4 ± 21.7 49.4 ± 33.1 184.0 ± 124.2 0.19 
Eotaxin 1932.7 ± 348.3 1699.6 ± 602.2 1648.1 ± 527.1 1949.3 ± 1433.4 0.93 
G-CSF 120.5 ± 37.2 176.8 ± 122.9 92.0 ± 44.0 653.7 ± 1056.1 0.29 
GM-CSF 172.5 ± 7.1 126.1 ± 76.5 159.7 ± 31.6 122.2 ± 65.1 0.68 
IFNγ 130.8 ± 46.3 107.9 ± 32.3 113.0 ± 22.3 177.3 ± 42.6 0.23 
KC 50.7 ± 11.0 56.1 ± 12.2 68.3 ± 10.6 77.0 ± 43.4 0.26 
MCP-1 411.8 ± 80.5 567.3 ± 115.0 608.5 ± 266.6 942.1 ± 294.8 0.25 
MIP1α 403.1 ± 86.8 329.1 ± 36.4 420.8 ± 102.6 580.1 ± 38.8 0.003* 
MIP1β 118.3 ± 26.3 137.6 ± 15.4 153.2 ± 30.7 919.7 ± 1227.9 0.02* 
RANTES 79.9 ± 34.8 165.3 ± 100.6 56.0 ± 28.4 252.0 ± 219.8 0.13 
TNFα 348.9 ± 38.4 476.4 ± 117.4 485.8 ± 152.0 5728.7 ± 8652.9 0.06 
Serum levels are given as picograms per milliliter. Values are expressed as means ± sd. P values 
comparing differences across groups were determined by ANOVA with Kruskal-Wallis post test 
or nonparametric equivalent. 
*P ≤ 0.05. 
  
Table 2. 
SNPs in HMOX1 and HMOX2 associated with decreased influenza vaccine response as 
measured by median (IQR) HI antibody titer in normal human subjects (n=147 total) 
SNP Chr Gene Major allele Minor allele 0 minor alleles 1 minor alleles 2 minor alleles P 
rs743811 22 HMOX1 A G 160 (80, 320) 80 (60, 160) 20 (20, 20) 0.017* 
     [n=77] [n=58] [n=12]  
rs2160567 16 HMOX2 A G 160 (80, 320) 80 (60, 160) 20 (20, 20) 0.014* 
     [n=62] [n=71] [n=14]  
HMOX1, heme oxygenase 1; HMOX2, heme oxygenase 2; chr, chromosome. 
*P ≤ 0.05; ordinal effects model. 
 
